


S5 One-way sensitivity analysis of higher unidentified reservoir

One-way sensitivity analysis of the incremental cost-effectiveness ratio (€/Qaly)



One-way sensitivity analysis of treatment immediately with DAAs after diagnosis versus delaying DAA treatment until F2 METAVIR stage with a cost-saving ICER of -8227/QALY. In both scenarios we simulate a group of individuals with undiagnosed/untreated HCV, the so called unidentified reservoir. We vary this from 0-100 and 0-2000. In addition, from 2016 onwards 6500 individuals are forced into the high risk groups of our model.